Filing summary: Catalyst Biosciences, Inc. — Form 10-K for fiscal year ended December 31, 2015
Entity mismatch: The request identifies GYRE THERAPEUTICS, INC., but the supplied filing is for Catalyst Biosciences, Inc. It reports the year ended December 31, 2015, not a standalone 2015 fourth quarter. The financial statements reflect Old Catalyst’s historical results before its August 20, 2015 merger with Targacept and do not include Targacept’s pre-merger historical results.
Business context and reporting period
Catalyst was a clinical-stage biotechnology company developing engineered protease medicines, principally for hemophilia and inflammatory conditions. Its lead candidate, CB 813d (Factor VIIa), completed a Phase 1 trial. CB 2679d/ISU 304 (Factor IX) was in advanced preclinical development; anti-C3 and Factor Xa programs were earlier-stage or deprioritized. The company had no approved products and no product-sales revenue. The audited financial statements received an unqualified opinion; the filing is dated March 9, 2016.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Contract revenue | $1.75 million | $1.81 million |
| Research and development expense | $5.96 million | $5.27 million |
| General and administrative expense | $9.59 million | $4.06 million |
| Operating loss | $13.80 million | $7.51 million |
| Net loss | $14.76 million | $6.61 million |
| Cash used in operating activities | $19.12 million | $6.39 million |
| Cash and cash equivalents plus short-term investments, at year-end | $32.50 million | $1.54 million |
No product gross margin is reported because the company had no product sales; contract revenue was its only reported revenue. The filing does not provide a meaningful commercial operating margin. Accumulated deficit was $131.0 million at year-end 2015.
Year-end restricted cash was $33.9 million, largely held in escrow for redeemable convertible notes and not freely available for operations. The notes had $33.7 million of principal outstanding at year-end, are non-interest-bearing, and are redeemable or convertible at holders’ option; remaining principal is payable at maturity in February 2018. Total liabilities were $38.1 million. Operating lease obligations totaled $1.59 million.
Material changes versus the prior comparable period
- Net loss more than doubled, rising $8.15 million to $14.76 million. Operating expenses increased 67%; G&A rose 137%, primarily due to merger-related and other professional costs and the public-company transition.
- R&D expense increased 13%, reflecting increased personnel and research activity. Management expected R&D expense to rise again in 2016, primarily due to CB 813d manufacturing.
- Operating cash use increased to $19.12 million, including effects of merger-related working-capital movements and a manufacturing prepayment. The merger substantially increased reported year-end cash and investments.
- Pfizer terminated its Factor VIIa collaboration effective June 1, 2015. The company recognized the remaining deferred Pfizer revenue by that date, so future revenue from that agreement was expected to end. Total contract revenue nevertheless declined only 3% in 2015, to $1.75 million.
- The August 2015 merger, reverse stock split, and conversion of Old Catalyst preferred stock into common stock materially changed the share count and capital structure; prior-year per-share results are not directly comparable.
Outlook, commentary, risks, contingencies, and unusual items
- Management expected available resources to fund operations for at least 15 months from year-end 2015, subject to assumptions, and stated that additional capital would be needed to complete development and commercialization. The company had no committed financing beyond the note arrangement and anticipated possible equity, debt, collaboration, or licensing financing.
- Management planned a CB 813d clinical efficacy trial in 2017 and expected ISU Abxis to initiate a Phase 1/2 study of CB 2679d/ISU 304 in 2016. These were forward-looking plans, not assured milestones.
- The company was transferring CB 813d manufacturing activities from Pfizer to a third party and negotiating for technology, materials, and know-how. A November 2015 agreement with a manufacturer committed the company to $1.5 million, including a $1.1 million prepayment. Delays or an unsuccessful transfer could impede development.
- A potential non-neutralizing anti-drug antibody signal in one CB 813d Phase 1 participant was not confirmed in a follow-up blood draw; further testing was planned. The single-dose study could not rule out immunological responses in future multi-dose trials.
- A European patent, with counterparts in several other countries, may cover CB 813d. An opposition proceeding sustained the patent; the company was considering an appeal, and the scope and relevance to CB 813d remained uncertain.
- The company delayed IND-enabling work on its anti-C3 DGF candidate and Factor Xa variants to prioritize the two hemophilia programs. It also cited clinical, regulatory, manufacturing, reimbursement, intellectual-property, collaboration, and financing risks typical of an early-stage biotech.
- The 10-K reports effective disclosure controls at the reasonable-assurance level, but no auditor attestation on internal control over financial reporting for 2015; management cited the reverse merger and transition. No material litigation or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm the issuer: this filing is Catalyst Biosciences, Inc. (ticker CBIO), not GYRE THERAPEUTICS, INC.; verify whether this is the intended filing.
- Check unrestricted liquidity separately from the $33.9 million of restricted cash, and assess the cash runway against operating cash use and planned clinical/manufacturing spending.
- Review the redeemable-note terms, escrow balance, redemption and conversion activity, and potential dilution; approximately $33.7 million remained outstanding at year-end.
- Track the CB 813d manufacturing transfer, confirmatory antibody testing, and timing and design of the planned efficacy trial.
- Verify progress and funding responsibilities under the ISU Abxis collaboration, including clinical-trial initiation and milestone conditions.
- Assess the Pfizer termination’s continuing effects, including any outstanding technology-transfer, milestone, royalty, or other obligations, and the identified patent issue involving CB 813d.